

Julia L Marcus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488014/publications.pdf>

Version: 2024-02-01

77
papers

3,532
citations

172443

29
h-index

149686

56
g-index

81
all docs

81
docs citations

81
times ranked

4194
citing authors

#	ARTICLE	IF	CITATIONS
1	No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1601-1603.	5.8	444
2	Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 39-46.	2.1	316
3	Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. <i>JAMA Network Open</i> , 2020, 3, e207954.	5.9	299
4	Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 540-546.	2.1	238
5	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. <i>PLoS ONE</i> , 2013, 8, e81997.	2.5	193
6	HIV infection and incidence of ischemic stroke. <i>Aids</i> , 2014, 28, 1911-1919.	2.2	108
7	Declining Relative Risk for Myocardial Infarction Among HIV-Positive Compared With HIV-Negative Individuals With Access to Care. <i>Clinical Infectious Diseases</i> , 2015, 60, 1278-1280.	5.8	105
8	Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study. <i>Lancet HIV</i> , 2019, 6, e688-e695.	4.7	105
9	Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. <i>Prevention Science</i> , 2017, 18, 737-747.	2.6	104
10	Infections Missed by Urethral-Only Screening for Chlamydia or Gonorrhea Detection Among Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2011, 38, 922-924.	1.7	81
11	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	3.1	76
12	Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 413-419.	2.1	75
13	Patterns and clinical consequences of discontinuing <sc>HIV</sc> preexposure prophylaxis during primary care. <i>Journal of the International AIDS Society</i> , 2019, 22, e25250.	3.0	74
14	Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. <i>AIDS and Behavior</i> , 2012, 16, 1243-1259.	2.7	71
15	Projected HIV and Bacterial Sexually Transmitted Infection Incidence Following COVID-19-Related Sexual Distancing and Clinical Service Interruption. <i>Journal of Infectious Diseases</i> , 2021, 223, 1019-1028.	4.0	69
16	Perceived Interruptions to HIV Prevention and Treatment Services Associated With COVID-19 for Gay, Bisexual, and Other Men Who Have Sex With Men in 20 Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 644-651.	2.1	69
17	Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic. <i>Current HIV/AIDS Reports</i> , 2020, 17, 171-179.	3.1	62
18	Incident Hepatitis C Virus Infections Among Users of HIV Preexposure Prophylaxis in a Clinical Practice Setting. <i>Clinical Infectious Diseases</i> , 2015, 60, 1728-1729.	5.8	55

#	ARTICLE	IF	CITATIONS
19	Risk Compensation and Clinical Decision Making – The Case of HIV Preexposure Prophylaxis. <i>New England Journal of Medicine</i> , 2019, 380, 510-512.	27.0	55
20	Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. <i>Public Health Reports</i> , 2018, 133, 452-460.	2.5	54
21	Helping our patients take <scp>HIV</scp> pre-exposure prophylaxis (<scp>PrEP</scp>): a systematic review of adherence interventions. <i>HIV Medicine</i> , 2014, 15, 385-395.	2.2	52
22	Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures. <i>Clinical Infectious Diseases</i> , 2017, 65, 1768-1769.	5.8	51
23	The Cost-Effectiveness of Screening Men Who Have Sex With Men for Rectal Chlamydial and Gonococcal Infection to Prevent HIV Infection. <i>Sexually Transmitted Diseases</i> , 2013, 40, 366-371.	1.7	47
24	Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System. <i>JAMA Network Open</i> , 2021, 4, e2122692.	5.9	47
25	Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population. <i>Clinical Infectious Diseases</i> , 2019, 68, 213-221.	5.8	46
26	Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 536-544.	1.2	45
27	<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> Transmission From the Female Oropharynx to the Male Urethra. <i>Sexually Transmitted Diseases</i> , 2011, 38, 372-373.	1.7	43
28	Prostate Cancer Incidence and Prostate-Specific Antigen Testing Among HIV-Positive and HIV-Negative Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 495-502.	2.1	38
29	Disparities in Uptake of HIV Preexposure Prophylaxis in a Large Integrated Health Care System. <i>American Journal of Public Health</i> , 2016, 106, e2-e3.	2.7	38
30	Words Matter: Putting an End to “Unsafe” and “Risky” Sex. <i>Sexually Transmitted Diseases</i> , 2020, 47, 1-31.7		29
31	Prevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 511-513.	4.4	27
32	Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2014, 9, e91513.	2.5	27
33	Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?. <i>Annals of Internal Medicine</i> , 2020, 172, 281.	3.9	24
34	Using HIV Risk Prediction Tools to Identify Candidates for Pre-Exposure Prophylaxis: Perspectives from Patients and Primary Care Providers. <i>AIDS Patient Care and STDs</i> , 2019, 33, 372-378.	2.5	21
35	Updated outcomes of partner notification for human immunodeficiency virus, San Francisco, 2004–2008. <i>Aids</i> , 2009, 23, 1024-1026.	2.2	20
36	Prioritising pleasure and correcting misinformation in the era of U=U. <i>Lancet HIV</i> , 2021, 8, e175-e180.	4.7	19

#	ARTICLE	IF	CITATIONS
37	Sentinel Surveillance of Rectal Chlamydia and Gonorrhea Among Males—San Francisco, 2005–2008. <i>Sexually Transmitted Diseases</i> , 2010, 37, 59-61.	1.7	17
38	Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. <i>Clinical Infectious Diseases</i> , 2020, 71, 2710-2712.	5.8	16
39	Patient-Led Decision-Making for HIV Preexposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2021, 18, 48-56.	3.1	15
40	Associations Among HIV Risk Perception, Sexual Health Efficacy, and Intent to Use PrEP Among Women: An Application of the Risk Perception Attitude Framework. <i>AIDS Education and Prevention</i> , 2020, 32, 392-402.	1.1	15
41	No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 927-935.	4.4	13
42	Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States. <i>Annals of Epidemiology</i> , 2018, 28, 830-832.	1.9	13
43	Screening Peter to Save Paul: The Population-Level Effects of Screening Men Who Have Sex With Men for Gonorrhea and Chlamydia. <i>Sexually Transmitted Diseases</i> , 2018, 45, 623-625.	1.7	12
44	Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. <i>International Journal of STD and AIDS</i> , 2019, 30, 689-695.	1.1	12
45	Gaps in Sexually Transmitted Infection Screening Among Men who Have Sex with Men in Pre-exposure Prophylaxis (PrEP) Care in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e2261-e2269.	5.8	12
46	Prediction Model to Maximize Impact of Syphilis Partner Notification—San Francisco, 2004–2008. <i>Sexually Transmitted Diseases</i> , 2010, 37, 109-114.	1.7	11
47	Nondaily Use of HIV Preexposure Prophylaxis in a Large Online Survey of Primarily Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 182-188.	2.1	11
48	Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program. <i>New England Journal of Medicine</i> , 2022, 386, 2064-2066.	27.0	10
49	HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 329-330.	1.1	9
50	Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. <i>Clinical Infectious Diseases</i> , 2020, 71, 3152-3153.	5.8	8
51	Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2188-2196.	2.5	8
52	Brief Report: “I Didn't Really Have a Primary Care Provider Until I Got PrEP” Patients' Perspectives on HIV Preexposure Prophylaxis as a Gateway to Health Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 31-35.	2.1	8
53	Kiss and Tell: Limited Empirical Data on Oropharyngeal <i>Neisseria gonorrhoeae</i> Among Men Who Have Sex With Men and Implications for Modeling. <i>Sexually Transmitted Diseases</i> , 2017, 44, 596-598.	1.7	7
54	Low-Intensity Outreach to Increase Uptake of HIV Preexposure Prophylaxis Among Patients with Sexually Transmitted Infections. <i>AIDS and Behavior</i> , 2019, 23, 544-547.	2.7	7

#	ARTICLE	IF	CITATIONS
55	National and International Dimensions of Human Immunodeficiency Virus-1 Sequence Clusters in a Northern California Clinical Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz135.	0.9	6
56	Alcohol and drug use, partner PrEP use and STI prevalence among people with HIV. <i>Sexually Transmitted Infections</i> , 2020, 96, 184-188.	1.9	6
57	Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007–2017. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa044.	0.9	6
58	A decision analytics model to optimize investment in interventions targeting the HIV preexposure prophylaxis cascade of care. <i>Aids</i> , 2021, 35, 1479-1489.	2.2	6
59	Evidence of Underreporting of Adverse Childhood Experiences, San Francisco Municipal STD Clinic, 2007. <i>Sexually Transmitted Diseases</i> , 2009, 36, 422-424.	1.7	5
60	Using HIV Testing History to Measure the Success of HIV Partner Services. <i>Sexually Transmitted Diseases</i> , 2013, 40, 419-421.	1.7	5
61	Recurrence after hospitalization for acute coronary syndrome among HIV-infected and HIV-uninfected individuals. <i>HIV Medicine</i> , 2019, 20, 19-26.	2.2	5
62	Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab372.	0.9	5
63	Making PrEP easy. <i>Lancet HIV</i> , 2022, 9, e226-e228.	4.7	4
64	Characteristics of Males Infected With Common <i>Neisseria gonorrhoeae</i> Sequence Types in the Gonococcal Isolate Surveillance Project, San Francisco, California, 2009. <i>American Journal of Epidemiology</i> , 2013, 178, 1289-1295.	3.4	3
65	HIV Preexposure Prophylaxis and Sexual Satisfaction Among Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2021, 48, e135-e137.	1.7	3
66	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 663-670.	2.1	3
67	What Has the Pandemic Revealed about the Shortcomings of Modern Epidemiology? What Can We Fix or Do Better?. <i>American Journal of Epidemiology</i> , 2022, 191, 980-986.	3.4	3
68	Ending a Failed Intervention: STD Performance Measures. <i>Sexually Transmitted Diseases</i> , 2011, 38, 887.	1.7	2
69	Preexposure Prophylaxis and Patient Centeredness. <i>American Journal of Men's Health</i> , 2016, 10, 353-358.	1.6	2
70	Machine Learning for Human Immunodeficiency Virus Prevention in Rural Africa: The SEARCH for Sustainability. <i>Clinical Infectious Diseases</i> , 2020, 71, 2334-2335.	5.8	2
71	Tenofovir Alafenamide for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 173, 78.	3.9	2
72	More Screening or More Disease? Gonorrhea Testing and Positivity Patterns Among Men in 3 Large Clinical Practices in Massachusetts, 2010–2017. <i>Clinical Infectious Diseases</i> , 2020, 71, e399-e405.	5.8	1

#	ARTICLE	IF	CITATIONS
73	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, e17-e21.	2.1	1
74	Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV. HIV Medicine, 2021, , .	2.2	1
75	Marcus et al. Respond. American Journal of Public Health, 2018, 108, e27-e28.	2.7	0
76	Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 2018, 155, 1646-1647.e2.	1.3	0
77	Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:. Dermatologic Clinics, 2020, 38, 233-238.	1.7	0